| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 4.47e-09 | 14 | 96 | 5 | GO:0005130 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 7.26e-08 | 23 | 96 | 5 | GO:0034235 | |
| GeneOntologyMolecularFunction | filamin binding | 2.51e-07 | 29 | 96 | 5 | GO:0031005 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 2.51e-07 | 29 | 96 | 5 | GO:0035325 | |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 5.76e-07 | 34 | 96 | 5 | GO:0015125 | |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 1.08e-06 | 70 | 96 | 6 | GO:1901618 | |
| GeneOntologyMolecularFunction | lipid transmembrane transporter activity | 1.38e-06 | 73 | 96 | 6 | GO:0170055 | |
| GeneOntologyMolecularFunction | glycolipid binding | 3.73e-06 | 49 | 96 | 5 | GO:0051861 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 7.07e-06 | 207 | 96 | 8 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 7.33e-06 | 208 | 96 | 8 | GO:0005342 | |
| GeneOntologyMolecularFunction | dihydrofolic acid binding | 6.84e-05 | 3 | 96 | 2 | GO:0051871 | |
| GeneOntologyMolecularFunction | dihydrofolate reductase activity | 6.84e-05 | 3 | 96 | 2 | GO:0004146 | |
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 7.36e-05 | 90 | 96 | 5 | GO:0008028 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 8.47e-05 | 293 | 96 | 8 | GO:0008514 | |
| GeneOntologyMolecularFunction | sequence-specific mRNA binding | 9.87e-05 | 19 | 96 | 3 | GO:1990825 | |
| GeneOntologyMolecularFunction | actin binding | 1.03e-04 | 479 | 96 | 10 | GO:0003779 | |
| GeneOntologyMolecularFunction | calmodulin binding | 1.23e-04 | 230 | 96 | 7 | GO:0005516 | |
| GeneOntologyMolecularFunction | phosphatidylinositol binding | 1.43e-04 | 316 | 96 | 8 | GO:0035091 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 3.69e-04 | 196 | 96 | 6 | GO:0005319 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 7.66e-04 | 149 | 96 | 5 | GO:1990782 | |
| GeneOntologyMolecularFunction | glycine transmembrane transporter activity | 1.00e-03 | 10 | 96 | 2 | GO:0015187 | |
| GeneOntologyMolecularFunction | neutral L-amino acid transmembrane transporter activity | 1.01e-03 | 41 | 96 | 3 | GO:0015175 | |
| GeneOntologyMolecularFunction | growth factor receptor binding | 1.49e-03 | 173 | 96 | 5 | GO:0070851 | |
| GeneOntologyMolecularFunction | acetyltransferase activity | 1.60e-03 | 104 | 96 | 4 | GO:0016407 | |
| GeneOntologyMolecularFunction | aromatic amino acid transmembrane transporter activity | 1.72e-03 | 13 | 96 | 2 | GO:0015173 | |
| GeneOntologyMolecularFunction | translation regulator activity, nucleic acid binding | 2.10e-03 | 112 | 96 | 4 | GO:0090079 | |
| GeneOntologyMolecularFunction | mRNA regulatory element binding translation repressor activity | 2.97e-03 | 17 | 96 | 2 | GO:0000900 | |
| GeneOntologyMolecularFunction | nucleoside-triphosphatase regulator activity | 3.08e-03 | 507 | 96 | 8 | GO:0060589 | |
| GeneOntologyMolecularFunction | GTPase regulator activity | 3.08e-03 | 507 | 96 | 8 | GO:0030695 | |
| GeneOntologyMolecularFunction | NADP binding | 3.32e-03 | 62 | 96 | 3 | GO:0050661 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor | 3.33e-03 | 18 | 96 | 2 | GO:0016646 | |
| GeneOntologyMolecularFunction | protein phosphatase binding | 3.46e-03 | 210 | 96 | 5 | GO:0019903 | |
| GeneOntologyMolecularFunction | folic acid binding | 4.11e-03 | 20 | 96 | 2 | GO:0005542 | |
| GeneOntologyMolecularFunction | L-amino acid transmembrane transporter activity | 4.86e-03 | 71 | 96 | 3 | GO:0015179 | |
| GeneOntologyMolecularFunction | phospholipid binding | 4.90e-03 | 548 | 96 | 8 | GO:0005543 | |
| GeneOntologyMolecularFunction | guanyl-nucleotide exchange factor activity | 5.17e-03 | 231 | 96 | 5 | GO:0005085 | |
| GeneOntologyMolecularFunction | acyltransferase activity, transferring groups other than amino-acyl groups | 5.85e-03 | 238 | 96 | 5 | GO:0016747 | |
| GeneOntologyMolecularFunction | N-acetyltransferase activity | 6.31e-03 | 78 | 96 | 3 | GO:0008080 | |
| GeneOntologyMolecularFunction | cytoskeletal protein binding | PSG1 MAP2 PSG3 MYO7A PSG4 PSG9 CEP290 KLHL3 DIAPH1 RACGAP1 PSG8 PACRG | 6.37e-03 | 1099 | 96 | 12 | GO:0008092 |
| GeneOntologyMolecularFunction | NADPH binding | 6.90e-03 | 26 | 96 | 2 | GO:0070402 | |
| GeneOntologyMolecularFunction | organic cation transmembrane transporter activity | 7.50e-03 | 83 | 96 | 3 | GO:0015101 | |
| GeneOntologyMolecularFunction | vitamin binding | 7.62e-03 | 161 | 96 | 4 | GO:0019842 | |
| GeneOntologyMolecularFunction | phosphatase binding | 8.96e-03 | 264 | 96 | 5 | GO:0019902 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on the CH-NH group of donors | 9.12e-03 | 30 | 96 | 2 | GO:0016645 | |
| GeneOntologyMolecularFunction | S-acyltransferase activity | 9.12e-03 | 30 | 96 | 2 | GO:0016417 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 3.61e-09 | 14 | 95 | 5 | GO:0070348 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 5.40e-09 | 15 | 95 | 5 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 5.40e-09 | 15 | 95 | 5 | GO:1903387 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 5.40e-09 | 15 | 95 | 5 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 5.40e-09 | 15 | 95 | 5 | GO:0002859 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 7.82e-09 | 16 | 95 | 5 | GO:0038016 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 1.10e-08 | 17 | 95 | 5 | GO:0070342 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 1.10e-08 | 17 | 95 | 5 | GO:1901143 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 1.10e-08 | 17 | 95 | 5 | GO:0038158 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 1.52e-08 | 18 | 95 | 5 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 2.74e-08 | 20 | 95 | 5 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 3.58e-08 | 21 | 95 | 5 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 3.58e-08 | 21 | 95 | 5 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 3.58e-08 | 21 | 95 | 5 | GO:0002838 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 4.61e-08 | 22 | 95 | 5 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 5.87e-08 | 23 | 95 | 5 | GO:0090331 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 5.87e-08 | 23 | 95 | 5 | GO:0002858 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 7.39e-08 | 24 | 95 | 5 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 7.39e-08 | 24 | 95 | 5 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 7.39e-08 | 24 | 95 | 5 | GO:0002420 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 9.20e-08 | 25 | 95 | 5 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 9.20e-08 | 25 | 95 | 5 | GO:0002423 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 1.39e-07 | 27 | 95 | 5 | GO:0070344 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 1.68e-07 | 28 | 95 | 5 | GO:0034111 | |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 2.03e-07 | 29 | 95 | 5 | GO:2001212 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 2.88e-07 | 31 | 95 | 5 | GO:0010544 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 3.33e-07 | 60 | 95 | 6 | GO:0030851 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 3.40e-07 | 32 | 95 | 5 | GO:0045779 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 3.40e-07 | 32 | 95 | 5 | GO:0070341 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 3.40e-07 | 32 | 95 | 5 | GO:0060312 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 3.99e-07 | 33 | 95 | 5 | GO:0030852 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 3.99e-07 | 33 | 95 | 5 | GO:2000252 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 4.67e-07 | 34 | 95 | 5 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 4.67e-07 | 34 | 95 | 5 | GO:0046851 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 5.42e-07 | 35 | 95 | 5 | GO:1901142 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 8.29e-07 | 38 | 95 | 5 | GO:2000345 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 9.48e-07 | 39 | 95 | 5 | GO:0045717 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 9.68e-07 | 114 | 95 | 7 | GO:0045824 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 1.08e-06 | 40 | 95 | 5 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 1.22e-06 | 41 | 95 | 5 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 1.39e-06 | 42 | 95 | 5 | GO:0090330 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 1.97e-06 | 45 | 95 | 5 | GO:0048521 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 2.20e-06 | 46 | 95 | 5 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 2.20e-06 | 46 | 95 | 5 | GO:0072574 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 2.45e-06 | 47 | 95 | 5 | GO:0001911 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 2.45e-06 | 47 | 95 | 5 | GO:0015721 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 2.45e-06 | 47 | 95 | 5 | GO:0034104 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 3.03e-06 | 49 | 95 | 5 | GO:0072576 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 3.03e-06 | 49 | 95 | 5 | GO:0002837 | |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 3.35e-06 | 50 | 95 | 5 | GO:0002834 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 4.08e-06 | 52 | 95 | 5 | GO:0031342 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 4.49e-06 | 53 | 95 | 5 | GO:0034110 | |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 5.91e-06 | 56 | 95 | 5 | GO:0002418 | |
| GeneOntologyBiologicalProcess | negative regulation of response to biotic stimulus | 6.32e-06 | 151 | 95 | 7 | GO:0002832 | |
| GeneOntologyBiologicalProcess | negative regulation of osteoclast differentiation | 7.67e-06 | 59 | 95 | 5 | GO:0045671 | |
| GeneOntologyBiologicalProcess | tetrahydrobiopterin biosynthetic process | 7.79e-06 | 9 | 95 | 3 | GO:0006729 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 8.33e-06 | 60 | 95 | 5 | GO:0045922 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 9.04e-06 | 61 | 95 | 5 | GO:0060259 | |
| GeneOntologyBiologicalProcess | tetrahydrobiopterin metabolic process | 1.11e-05 | 10 | 95 | 3 | GO:0046146 | |
| GeneOntologyBiologicalProcess | regulation of platelet activation | 1.33e-05 | 66 | 95 | 5 | GO:0010543 | |
| GeneOntologyBiologicalProcess | regulation of endothelial cell differentiation | 1.44e-05 | 67 | 95 | 5 | GO:0045601 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 1.66e-05 | 69 | 95 | 5 | GO:0030195 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 1.78e-05 | 70 | 95 | 5 | GO:0045124 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 1.78e-05 | 70 | 95 | 5 | GO:1900047 | |
| GeneOntologyBiologicalProcess | regulation of vascular permeability | 1.91e-05 | 71 | 95 | 5 | GO:0043114 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 1.91e-05 | 71 | 95 | 5 | GO:0002347 | |
| GeneOntologyBiologicalProcess | negative regulation of coagulation | 2.04e-05 | 72 | 95 | 5 | GO:0050819 | |
| GeneOntologyBiologicalProcess | negative regulation of interleukin-1 production | 2.04e-05 | 72 | 95 | 5 | GO:0032692 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid biosynthetic process | 2.19e-05 | 73 | 95 | 5 | GO:0042304 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 2.66e-05 | 76 | 95 | 5 | GO:0042269 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 3.41e-05 | 80 | 95 | 5 | GO:0002715 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 3.41e-05 | 80 | 95 | 5 | GO:0046850 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 4.07e-05 | 83 | 95 | 5 | GO:0002707 | |
| GeneOntologyBiologicalProcess | negative regulation of myeloid leukocyte differentiation | 4.57e-05 | 85 | 95 | 5 | GO:0002762 | |
| GeneOntologyBiologicalProcess | regulation of sprouting angiogenesis | 4.57e-05 | 85 | 95 | 5 | GO:1903670 | |
| GeneOntologyBiologicalProcess | regulation of epidermal growth factor receptor signaling pathway | 4.83e-05 | 86 | 95 | 5 | GO:0042058 | |
| GeneOntologyBiologicalProcess | blood vessel remodeling | 5.11e-05 | 87 | 95 | 5 | GO:0001974 | |
| GeneOntologyBiologicalProcess | energy homeostasis | 5.44e-05 | 144 | 95 | 6 | GO:0097009 | |
| GeneOntologyBiologicalProcess | carboxylic acid biosynthetic process | 5.73e-05 | 374 | 95 | 9 | GO:0046394 | |
| GeneOntologyBiologicalProcess | organic acid biosynthetic process | 6.09e-05 | 377 | 95 | 9 | GO:0016053 | |
| GeneOntologyBiologicalProcess | pteridine-containing compound biosynthetic process | 6.14e-05 | 17 | 95 | 3 | GO:0042559 | |
| GeneOntologyBiologicalProcess | response to methotrexate | 6.28e-05 | 3 | 95 | 2 | GO:0031427 | |
| GeneOntologyBiologicalProcess | small molecule biosynthetic process | PSG1 PSG3 PSG4 SPR PSG9 CYP39A1 ABCG4 FASN DHFR DHFR2 PSG8 MVK | 6.34e-05 | 676 | 95 | 12 | GO:0044283 |
| GeneOntologyBiologicalProcess | negative regulation of lipid biosynthetic process | 6.34e-05 | 91 | 95 | 5 | GO:0051055 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 6.34e-05 | 91 | 95 | 5 | GO:0030193 | |
| GeneOntologyBiologicalProcess | regulation of ERBB signaling pathway | 7.03e-05 | 93 | 95 | 5 | GO:1901184 | |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 7.03e-05 | 93 | 95 | 5 | GO:1900046 | |
| GeneOntologyBiologicalProcess | platelet aggregation | 7.79e-05 | 95 | 95 | 5 | GO:0070527 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 8.18e-05 | 96 | 95 | 5 | GO:0002704 | |
| GeneOntologyBiologicalProcess | regulation of coagulation | 8.18e-05 | 96 | 95 | 5 | GO:0050818 | |
| GeneOntologyBiologicalProcess | negative regulation of wound healing | 9.03e-05 | 98 | 95 | 5 | GO:0061045 | |
| GeneOntologyBiologicalProcess | endothelial cell differentiation | 9.10e-05 | 158 | 95 | 6 | GO:0045446 | |
| GeneOntologyBiologicalProcess | bone resorption | 9.47e-05 | 99 | 95 | 5 | GO:0045453 | |
| GeneOntologyBiologicalProcess | feeding behavior | 1.04e-04 | 162 | 95 | 6 | GO:0007631 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response | 1.19e-04 | 239 | 95 | 7 | GO:0050777 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 1.25e-04 | 105 | 95 | 5 | GO:0042267 | |
| GeneOntologyBiologicalProcess | dihydrofolate metabolic process | 1.25e-04 | 4 | 95 | 2 | GO:0046452 | |
| GeneOntologyBiologicalProcess | negative regulation of T cell proliferation | 1.37e-04 | 107 | 95 | 5 | GO:0042130 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immunity | 1.49e-04 | 109 | 95 | 5 | GO:0002228 | |
| GeneOntologyBiologicalProcess | anatomical structure homeostasis | 1.56e-04 | 334 | 95 | 8 | GO:0060249 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 7.72e-09 | 16 | 96 | 5 | GO:0070021 | |
| GeneOntologyCellularComponent | ciliary membrane | 6.00e-06 | 98 | 96 | 6 | GO:0060170 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 5.94e-05 | 90 | 96 | 5 | GO:0016328 | |
| GeneOntologyCellularComponent | serine/threonine protein kinase complex | 8.66e-05 | 157 | 96 | 6 | GO:1902554 | |
| GeneOntologyCellularComponent | protein kinase complex | 1.34e-04 | 170 | 96 | 6 | GO:1902911 | |
| GeneOntologyCellularComponent | cell projection membrane | 1.65e-04 | 431 | 96 | 9 | GO:0031253 | |
| GeneOntologyCellularComponent | T cell receptor complex | 9.36e-04 | 163 | 96 | 5 | GO:0042101 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 2.13e-08 | 17 | 74 | 5 | MP:0031047 | |
| MousePheno | increased skeletal muscle triglyceride level | 6.90e-08 | 21 | 74 | 5 | MP:0031415 | |
| MousePheno | decreased fatty acid oxidation | 1.42e-07 | 24 | 74 | 5 | MP:0014172 | |
| MousePheno | increased abdominal fat pad weight | 2.67e-07 | 27 | 74 | 5 | MP:0009286 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 3.24e-07 | 28 | 74 | 5 | MP:0020950 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 5.53e-07 | 31 | 74 | 5 | MP:0031413 | |
| MousePheno | decreased carbon dioxide production | 5.53e-07 | 31 | 74 | 5 | MP:0008964 | |
| MousePheno | decreased skeletal muscle cell glucose uptake | 1.04e-06 | 35 | 74 | 5 | MP:0031618 | |
| MousePheno | abnormal muscle triglyceride level | 1.20e-06 | 36 | 74 | 5 | MP:0031412 | |
| MousePheno | decreased muscle cell glucose uptake | 1.81e-06 | 39 | 74 | 5 | MP:0030022 | |
| MousePheno | decreased susceptibility to Riboviria infection induced morbidity/mortality | 3.35e-06 | 44 | 74 | 5 | MP:0031023 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 4.68e-06 | 47 | 74 | 5 | MP:0031617 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 5.77e-06 | 49 | 74 | 5 | MP:0020948 | |
| MousePheno | decreased cellular glucose uptake | 8.53e-06 | 53 | 74 | 5 | MP:0003926 | |
| MousePheno | abnormal fatty acid oxidation | 9.37e-06 | 54 | 74 | 5 | MP:0010953 | |
| MousePheno | decreased susceptibility to viral infection induced morbidity/mortality | 1.58e-05 | 60 | 74 | 5 | MP:0009790 | |
| MousePheno | abnormal lipid oxidation | 1.71e-05 | 61 | 74 | 5 | MP:0010951 | |
| MousePheno | increased insulin secretion | 2.17e-05 | 64 | 74 | 5 | MP:0003058 | |
| MousePheno | decreased respiratory quotient | 2.48e-05 | 110 | 74 | 6 | MP:0010379 | |
| MousePheno | abnormal muscle cell glucose uptake | 2.71e-05 | 67 | 74 | 5 | MP:0004130 | |
| MousePheno | abnormal carbon dioxide production | 2.71e-05 | 67 | 74 | 5 | MP:0008962 | |
| MousePheno | abnormal vascular wound healing | 4.11e-05 | 73 | 74 | 5 | MP:0004883 | |
| MousePheno | decreased susceptibility to viral infection | 5.11e-05 | 125 | 74 | 6 | MP:0002410 | |
| MousePheno | decreased oxygen consumption | 6.02e-05 | 79 | 74 | 5 | MP:0005290 | |
| MousePheno | increased food intake | 6.19e-05 | 189 | 74 | 7 | MP:0011939 | |
| MousePheno | polyphagia | 6.40e-05 | 80 | 74 | 5 | MP:0001433 | |
| MousePheno | decreased susceptibility to Riboviria infection | 7.20e-05 | 82 | 74 | 5 | MP:0020914 | |
| MousePheno | increased incidence of tumors by chemical induction | 9.98e-05 | 141 | 74 | 6 | MP:0004499 | |
| MousePheno | increased lean body mass | 1.00e-04 | 354 | 74 | 9 | MP:0003960 | |
| MousePheno | abnormal susceptibility to viral infection | 1.10e-04 | 279 | 74 | 8 | MP:0020185 | |
| MousePheno | abnormal glycogen homeostasis | 1.12e-04 | 144 | 74 | 6 | MP:0005438 | |
| MousePheno | abnormal lean body mass | PSG1 PSG3 PSG4 PSG9 MSTN OGDH CBX6 MCU AP1G2 PSG8 ATL2 VPS13B DOP1B | 1.36e-04 | 749 | 74 | 13 | MP:0003959 |
| MousePheno | abnormal cellular glucose uptake | 2.03e-04 | 102 | 74 | 5 | MP:0003925 | |
| MousePheno | abnormal hepatoblast morphology | 2.74e-04 | 5 | 74 | 2 | MP:0012240 | |
| MousePheno | increased body size | 2.96e-04 | 409 | 74 | 9 | MP:0001264 | |
| MousePheno | increased incidence of induced tumors | 3.04e-04 | 173 | 74 | 6 | MP:0002021 | |
| MousePheno | obese | 3.26e-04 | 113 | 74 | 5 | MP:0001261 | |
| MousePheno | abnormal respiratory quotient | 3.54e-04 | 178 | 74 | 6 | MP:0004129 | |
| MousePheno | increased total body fat amount | 3.85e-04 | 424 | 74 | 9 | MP:0010024 | |
| MousePheno | abnormal pancreas secretion | 4.11e-04 | 183 | 74 | 6 | MP:0002694 | |
| MousePheno | decreased energy expenditure | 4.14e-04 | 119 | 74 | 5 | MP:0004890 | |
| MousePheno | decreased susceptibility to infection induced morbidity/mortality | 4.31e-04 | 120 | 74 | 5 | MP:0009786 | |
| MousePheno | increased circulating leptin level | 5.19e-04 | 125 | 74 | 5 | MP:0005669 | |
| MousePheno | abnormal platelet ADP level | 5.71e-04 | 7 | 74 | 2 | MP:0009556 | |
| MousePheno | decreased platelet ADP level | 5.71e-04 | 7 | 74 | 2 | MP:0009557 | |
| MousePheno | retina rod cell degeneration | 5.75e-04 | 31 | 74 | 3 | MP:0008451 | |
| MousePheno | insulin resistance | 6.07e-04 | 197 | 74 | 6 | MP:0005331 | |
| MousePheno | decreased circulating triglyceride level | 6.17e-04 | 275 | 74 | 7 | MP:0002644 | |
| MousePheno | abnormal susceptibility to infection induced morbidity/mortality | 6.73e-04 | 279 | 74 | 7 | MP:0009785 | |
| MousePheno | abnormal retina rod cell morphology | 7.68e-04 | 78 | 74 | 4 | MP:0001005 | |
| MousePheno | impaired glucose tolerance | 9.38e-04 | 480 | 74 | 9 | MP:0005293 | |
| MousePheno | abnormal food intake | 9.51e-04 | 481 | 74 | 9 | MP:0005449 | |
| MousePheno | decreased granulocyte monocyte progenitor cell number | 9.72e-04 | 9 | 74 | 2 | MP:0013697 | |
| MousePheno | abnormal colon morphology | 1.25e-03 | 152 | 74 | 5 | MP:0000495 | |
| MousePheno | belly spot | 1.31e-03 | 41 | 74 | 3 | MP:0000373 | |
| MousePheno | abnormal adipose tissue amount | PSG1 PSG3 PSG4 PSG9 MSTN OGDH EPG5 TELO2 CBX6 MCU DOCK7 PSG8 ATL2 VPS13B | 1.38e-03 | 1077 | 74 | 14 | MP:0005452 |
| MousePheno | abnormal circulating leptin level | 1.55e-03 | 236 | 74 | 6 | MP:0005667 | |
| MousePheno | abnormal folic acid level | 1.76e-03 | 12 | 74 | 2 | MP:0011230 | |
| Domain | ARM-type_fold | RELCH MROH2A USP24 NOP9 MROH1 MROH6 TELO2 MROH2B EIF2B5 DIAPH1 AP1G2 | 1.34e-06 | 339 | 96 | 11 | IPR016024 |
| Domain | DHFR_1 | 2.61e-05 | 2 | 96 | 2 | PF00186 | |
| Domain | DHFR_1 | 2.61e-05 | 2 | 96 | 2 | PS00075 | |
| Domain | DHFR_dom | 2.61e-05 | 2 | 96 | 2 | IPR001796 | |
| Domain | DHFR_2 | 2.61e-05 | 2 | 96 | 2 | PS51330 | |
| Domain | - | 2.61e-05 | 2 | 96 | 2 | 3.40.430.10 | |
| Domain | DHFR-like_dom | 2.61e-05 | 2 | 96 | 2 | IPR024072 | |
| Domain | DHFR | 2.61e-05 | 2 | 96 | 2 | IPR012259 | |
| Domain | Ig_2 | 3.68e-05 | 73 | 96 | 5 | PF13895 | |
| Domain | ARM-like | 7.60e-05 | 270 | 96 | 8 | IPR011989 | |
| Domain | Rho_GTPase_activation_prot | 9.03e-05 | 88 | 96 | 5 | IPR008936 | |
| Domain | - | 1.48e-04 | 222 | 96 | 7 | 1.25.10.10 | |
| Domain | RhoGAP | 2.91e-04 | 62 | 96 | 4 | SM00324 | |
| Domain | RhoGAP | 3.10e-04 | 63 | 96 | 4 | PF00620 | |
| Domain | RhoGAP_dom | 3.29e-04 | 64 | 96 | 4 | IPR000198 | |
| Domain | RHOGAP | 3.29e-04 | 64 | 96 | 4 | PS50238 | |
| Domain | - | 3.29e-04 | 64 | 96 | 4 | 1.10.555.10 | |
| Domain | DUF3398 | 3.87e-04 | 6 | 96 | 2 | PF11878 | |
| Domain | DOCK_C/D_N | 3.87e-04 | 6 | 96 | 2 | IPR021816 | |
| Domain | HEAT_REPEAT | 4.64e-04 | 70 | 96 | 4 | PS50077 | |
| Domain | IGc2 | 1.34e-03 | 235 | 96 | 6 | SM00408 | |
| Domain | Ig_sub2 | 1.34e-03 | 235 | 96 | 6 | IPR003598 | |
| Domain | DHR-1_domain | 1.40e-03 | 11 | 96 | 2 | IPR027007 | |
| Domain | DHR_2 | 1.40e-03 | 11 | 96 | 2 | PS51651 | |
| Domain | DHR_1 | 1.40e-03 | 11 | 96 | 2 | PS51650 | |
| Domain | DHR-2 | 1.40e-03 | 11 | 96 | 2 | PF06920 | |
| Domain | DOCK | 1.40e-03 | 11 | 96 | 2 | IPR026791 | |
| Domain | DOCK_C | 1.40e-03 | 11 | 96 | 2 | IPR010703 | |
| Domain | DOCK-C2 | 1.40e-03 | 11 | 96 | 2 | PF14429 | |
| Domain | DHR-2 | 1.40e-03 | 11 | 96 | 2 | IPR027357 | |
| Domain | PSI | 1.50e-03 | 44 | 96 | 3 | IPR016201 | |
| Domain | - | MYO7A DHX57 CHD3 SRCAP ABCG4 LRGUK MTIF2 GAL3ST3 NLRC5 ATL2 NLRP8 | 1.54e-03 | 746 | 96 | 11 | 3.40.50.300 |
| Domain | PSI | 1.70e-03 | 46 | 96 | 3 | SM00423 | |
| Domain | V-set | 2.61e-03 | 184 | 96 | 5 | PF07686 | |
| Domain | ig | 2.99e-03 | 190 | 96 | 5 | PF00047 | |
| Domain | Immunoglobulin | 2.99e-03 | 190 | 96 | 5 | IPR013151 | |
| Domain | HEAT_type_2 | 3.38e-03 | 17 | 96 | 2 | IPR021133 | |
| Domain | Ig_V-set | 3.65e-03 | 199 | 96 | 5 | IPR013106 | |
| Domain | Chromodomain_CS | 3.79e-03 | 18 | 96 | 2 | IPR023779 | |
| Domain | P-loop_NTPase | MYO7A DHX57 CHD3 SRCAP ABCG4 LRGUK MTIF2 GAL3ST3 NLRC5 ATL2 NLRP8 | 4.14e-03 | 848 | 96 | 11 | IPR027417 |
| Domain | EPHD | 5.65e-03 | 22 | 96 | 2 | PS51805 | |
| Pathway | REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS | 1.63e-05 | 99 | 77 | 6 | MM14624 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 2.42e-05 | 158 | 77 | 7 | MM14812 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 8.94e-05 | 194 | 77 | 7 | M16312 | |
| Pathway | REACTOME_RHOA_GTPASE_CYCLE | 1.24e-04 | 142 | 77 | 6 | MM15576 | |
| Pathway | REACTOME_RHO_GTPASE_CYCLE | SH3RF1 TAGAP ARHGAP9 PARD6A DOCK7 DIAPH1 RACGAP1 ARHGAP18 DOCK6 PKN3 | 1.31e-04 | 439 | 77 | 10 | MM15595 |
| Pathway | REACTOME_CDC42_GTPASE_CYCLE | 1.60e-04 | 94 | 77 | 5 | MM15598 | |
| Pathway | REACTOME_RHO_GTPASE_CYCLE | SH3RF1 TAGAP ARHGAP9 PARD6A DOCK7 DIAPH1 RACGAP1 ARHGAP18 DOCK6 PKN3 | 1.61e-04 | 450 | 77 | 10 | M27078 |
| Pathway | REACTOME_RHOA_GTPASE_CYCLE | 1.61e-04 | 149 | 77 | 6 | M41805 | |
| Pathway | REACTOME_CDC42_GTPASE_CYCLE | 2.00e-04 | 155 | 77 | 6 | M41808 | |
| Pathway | REACTOME_RAC1_GTPASE_CYCLE | 3.84e-04 | 175 | 77 | 6 | MM15599 | |
| Pathway | REACTOME_RAC1_GTPASE_CYCLE | 5.01e-04 | 184 | 77 | 6 | M41809 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 5.12e-04 | 258 | 77 | 7 | MM14572 | |
| Pathway | REACTOME_RHOC_GTPASE_CYCLE | 5.74e-04 | 70 | 77 | 4 | MM15597 | |
| Pathway | REACTOME_RHOC_GTPASE_CYCLE | 7.09e-04 | 74 | 77 | 4 | M41807 | |
| Pathway | REACTOME_HEMOSTASIS | 1.05e-03 | 571 | 77 | 10 | MM14472 | |
| Pubmed | 1.26e-12 | 14 | 98 | 6 | 29907459 | ||
| Pubmed | Insulin acutely decreases hepatic fatty acid synthase activity. | 2.10e-12 | 15 | 98 | 6 | 16054098 | |
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 2.03e-10 | 13 | 98 | 5 | 34058224 | |
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 2.03e-10 | 13 | 98 | 5 | 1985902 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 10964771 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 32169849 | ||
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 2.03e-10 | 13 | 98 | 5 | 19273835 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 2.03e-10 | 13 | 98 | 5 | 16638824 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 20044046 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 32150576 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 22469976 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 6265583 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 2.03e-10 | 13 | 98 | 5 | 21532628 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 2.03e-10 | 13 | 98 | 5 | 28035001 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 2.03e-10 | 13 | 98 | 5 | 12832451 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 25406283 | ||
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 2.03e-10 | 13 | 98 | 5 | 15316023 | |
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 2.03e-10 | 13 | 98 | 5 | 21670291 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 22162753 | ||
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 2.03e-10 | 13 | 98 | 5 | 23935487 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 2702644 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 8380065 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 1279194 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 15331748 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 2.03e-10 | 13 | 98 | 5 | 22406619 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 7628460 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 25724769 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 26374765 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 2.03e-10 | 13 | 98 | 5 | 25972571 | |
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 2.03e-10 | 13 | 98 | 5 | 22092845 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 11801635 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 28913658 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 19008452 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 18544705 | ||
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 2.03e-10 | 13 | 98 | 5 | 15220458 | |
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 2.03e-10 | 13 | 98 | 5 | 8500759 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 18843289 | ||
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 2.03e-10 | 13 | 98 | 5 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 2.03e-10 | 13 | 98 | 5 | 23800882 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 15207636 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 19285068 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 21760897 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 1719235 | ||
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 2.03e-10 | 13 | 98 | 5 | 1326665 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 21081647 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 11133662 | ||
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 2.03e-10 | 13 | 98 | 5 | 39168268 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 11483763 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 8402684 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 2164599 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 16619040 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 29377208 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 2.03e-10 | 13 | 98 | 5 | 8209741 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 2.03e-10 | 13 | 98 | 5 | 21949477 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 29396368 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 26219866 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 18003729 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 26284027 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 2133556 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 32521208 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 2.03e-10 | 13 | 98 | 5 | 33352461 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 19406938 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 38381498 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 20739537 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 19621080 | ||
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 2.03e-10 | 13 | 98 | 5 | 29967450 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 1633107 | ||
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 2.03e-10 | 13 | 98 | 5 | 19358828 | |
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 2.03e-10 | 13 | 98 | 5 | 27695943 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 20404914 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 16680193 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 26911181 | ||
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 1653760 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 2.03e-10 | 13 | 98 | 5 | 32027621 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 30664851 | ||
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 2.03e-10 | 13 | 98 | 5 | 27777319 | |
| Pubmed | 2.03e-10 | 13 | 98 | 5 | 18848945 | ||
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 37531413 | ||
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 23780386 | ||
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 28567513 | ||
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 8207827 | ||
| Pubmed | Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. | 3.14e-10 | 14 | 98 | 5 | 34666041 | |
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 19700760 | ||
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 34619794 | ||
| Pubmed | Expression patterns of CD66a and CD117 in the mouse submandibular gland. | 3.14e-10 | 14 | 98 | 5 | 25498293 | |
| Pubmed | Endothelial barrier function is differentially regulated by CEACAM1-mediated signaling. | 3.14e-10 | 14 | 98 | 5 | 29746166 | |
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 9212243 | ||
| Pubmed | CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo. | 3.14e-10 | 14 | 98 | 5 | 27572314 | |
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 1648219 | ||
| Pubmed | SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. | 3.14e-10 | 14 | 98 | 5 | 17081782 | |
| Pubmed | Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. | 3.14e-10 | 14 | 98 | 5 | 32209360 | |
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 11994468 | ||
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 11850617 | ||
| Pubmed | CEACAM2 positively regulates integrin αIIbβ3-mediated platelet functions. | 3.14e-10 | 14 | 98 | 5 | 27161904 | |
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 20381490 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 3.14e-10 | 14 | 98 | 5 | 26196244 | |
| Pubmed | 3.14e-10 | 14 | 98 | 5 | 8896983 | ||
| Interaction | PSG4 interactions | 3.20e-08 | 8 | 95 | 4 | int:PSG4 | |
| Interaction | PSG3 interactions | 3.18e-06 | 22 | 95 | 4 | int:PSG3 | |
| Interaction | TOP3B interactions | SH3RF1 MYO7A HECTD4 PER1 DHX57 SRCAP PLXNB2 KMT2C FASN MROH1 MROH6 USP40 SNRNP40 NLRC5 RACGAP1 AP1G2 SLC7A5 STK40 DOCK6 WNK2 PKN3 | 3.76e-06 | 1470 | 95 | 21 | int:TOP3B |
| Interaction | PSG1 interactions | 4.14e-06 | 51 | 95 | 5 | int:PSG1 | |
| Cytoband | 19q13.2 | 2.84e-05 | 164 | 98 | 5 | 19q13.2 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 2.33e-10 | 11 | 65 | 5 | 1315 | |
| GeneFamily | Maestro heat like repeat containing | 4.93e-08 | 11 | 65 | 4 | 636 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 2.99e-04 | 163 | 65 | 5 | 590 | |
| GeneFamily | Olfactory receptors, family 56 | 4.51e-04 | 9 | 65 | 2 | 167 | |
| GeneFamily | Rho GTPase activating proteins|BCH domain containing | 7.70e-04 | 50 | 65 | 3 | 721 | |
| GeneFamily | NLR family | 3.62e-03 | 25 | 65 | 2 | 666 | |
| GeneFamily | PHD finger proteins | 4.17e-03 | 90 | 65 | 3 | 88 | |
| GeneFamily | Zinc fingers MYND-type|A-kinase anchoring proteins | 4.85e-03 | 29 | 65 | 2 | 396 | |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 1.23e-07 | 32 | 98 | 5 | MM2 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 1.96e-07 | 35 | 98 | 5 | MM757 | |
| Coexpression | WANG_RESPONSE_TO_BEXAROTENE_UP | 9.94e-07 | 48 | 98 | 5 | MM531 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_DN | 2.31e-06 | 159 | 98 | 7 | MM760 | |
| Coexpression | BYSTROEM_CORRELATED_WITH_IL5_DN | 9.25e-06 | 75 | 98 | 5 | MM605 | |
| Coexpression | KUMAR_TARGETS_OF_MLL_AF9_FUSION | 9.40e-06 | 463 | 98 | 10 | MM1011 | |
| Coexpression | BOYLAN_MULTIPLE_MYELOMA_PCA3_DN | 1.91e-05 | 87 | 98 | 5 | MM851 | |
| Coexpression | THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_DN | VIPR1 RELCH HECTD4 ARHGAP9 PLXNB2 KLHL3 UBA7 CBX6 HPS1 NLRC5 AP1G2 | 2.54e-05 | 634 | 98 | 11 | M40866 |
| Coexpression | DESCARTES_FETAL_PLACENTA_TROPHOBLAST_GIANT_CELLS | 2.64e-05 | 93 | 98 | 5 | M40279 | |
| Coexpression | LIM_MAMMARY_STEM_CELL_DN | 3.82e-05 | 436 | 98 | 9 | MM1326 | |
| Coexpression | MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP | 6.40e-05 | 182 | 98 | 6 | MM993 | |
| Coexpression | HEVNER_INTERMEDIATE_ZONE_AND_UP_POSTMITOTIC_NEURONS | 9.83e-05 | 64 | 98 | 4 | MM408 | |
| Coexpression | GSE27786_BCELL_VS_NKTCELL_DN | 1.08e-04 | 200 | 98 | 6 | M4809 | |
| Coexpression | GSE29164_UNTREATED_VS_CD8_TCELL_AND_IL12_TREATED_MELANOMA_DAY3_DN | 1.08e-04 | 200 | 98 | 6 | M8485 | |
| Coexpression | GSE2770_IL12_VS_TGFB_AND_IL12_TREATED_ACT_CD4_TCELL_48H_UP | 1.08e-04 | 200 | 98 | 6 | M6027 | |
| Coexpression | OHGUCHI_LIVER_HNF4A_TARGETS_DN | 1.11e-04 | 201 | 98 | 6 | MM1294 | |
| Coexpression | BROWN_MYELOID_CELL_DEVELOPMENT_UP | 1.11e-04 | 201 | 98 | 6 | MM1006 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP | 1.21e-04 | 128 | 98 | 5 | MM1000 | |
| Coexpression | THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_DN | VIPR1 RELCH PLXNB2 ITIH5 KLHL3 UBA7 CBX6 HPS1 NLRC5 AP1G2 STK40 DOP1B | 1.42e-04 | 905 | 98 | 12 | M40865 |
| Coexpression | HOLLERN_EMT_BREAST_TUMOR_DN | 1.56e-04 | 135 | 98 | 5 | MM965 | |
| Coexpression | DESCARTES_FETAL_ADRENAL_CSH1_CSH2_POSITIVE_CELLS | 1.99e-04 | 224 | 98 | 6 | M40145 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_5_6WK_UP | 2.04e-04 | 143 | 98 | 5 | MM989 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Intercalated_Cell_Type_B|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.57e-06 | 176 | 98 | 6 | 6c7edf1cb38644500bce6c5a1dd90bbe17415cdb | |
| ToppCell | TCGA-Thryoid-Primary_Tumor-Thyroid_Papillary_Carcinoma-Classical-4|TCGA-Thryoid / Sample_Type by Project: Shred V9 | 3.32e-06 | 184 | 98 | 6 | d9659d1e4465fec68f48a22edef443f354f6c7cf | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.50e-06 | 194 | 98 | 6 | 46070fbb0ee0eb9e1801c43b73a15707471056dc | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.50e-06 | 194 | 98 | 6 | abacb6a8d7a9003f2f6c2be0305507f1c1c50347 | |
| ToppCell | P28-Epithelial-airway_epithelial_cell-ciliated_cell_of_airway|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 3.51e-05 | 168 | 98 | 5 | 8c8dbdbc7053f34e4ca0c5067af502fbea109fc1 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Intercalated_Cell_Type_B|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.62e-05 | 178 | 98 | 5 | 3d6d03bc57062f74ba19fc675dd36b12b6c7115d | |
| ToppCell | Calu_3-infected|Calu_3 / Cell line, Condition and Strain | 5.27e-05 | 183 | 98 | 5 | 8f7f5000645f24f20a8d7700c4df1f8953a1780b | |
| ToppCell | Somatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial-Endo_L2-5_CLDN5|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.69e-05 | 186 | 98 | 5 | 422d24e3e1a9397bb7d5c7ef75de2fd7ae8e136d | |
| ToppCell | Somatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.69e-05 | 186 | 98 | 5 | 65da0666a10a59f8cc379589860a2e98fe487754 | |
| ToppCell | Somatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.69e-05 | 186 | 98 | 5 | dc84fef1ca2f5d5d818b76a3321559e87d1c4a4d | |
| ToppCell | facs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l20-23|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.84e-05 | 187 | 98 | 5 | 69b47f00598d647e2a99427ebddf42c339428e47 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Cortical_Collecting_Duct_Intercalated_Cell_Type_A|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 5.84e-05 | 187 | 98 | 5 | 7b0168bdaa7c6c6b39878aff6a17f0943189a380 | |
| ToppCell | COVID-19-kidney-CD-IC-B|kidney / Disease (COVID-19 only), tissue and cell type | 5.84e-05 | 187 | 98 | 5 | ce05b89860573fe0356102e2998d1ef6d1968034 | |
| ToppCell | droplet-Marrow-BM_(NON-STC)-30m-Hematologic-erythroblast|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.45e-05 | 191 | 98 | 5 | 24ebc8d4a9fc3782510162e04fe586f7cb371eed | |
| ToppCell | droplet-Marrow-BM-1m-Hematologic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.61e-05 | 192 | 98 | 5 | ced2fdbcb181ac250ff50cd4d5d886e568924203 | |
| ToppCell | droplet-Marrow-BM-1m-Hematologic-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.61e-05 | 192 | 98 | 5 | 19b8675ed8a99bd3d08ad043e4ec9f006426c22f | |
| ToppCell | kidney_cells-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.61e-05 | 192 | 98 | 5 | 4842a55650fc4687c9184d498a8c05c259d15186 | |
| ToppCell | severe-low-quality_cells|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 6.78e-05 | 193 | 98 | 5 | 9337bc93e3904c7fc7c93c328518bcd6453b1e8c | |
| ToppCell | COVID-19_Mild|World / Disease condition and Cell class | 6.78e-05 | 193 | 98 | 5 | 7256a5a491536c525b31ae96d47ab5c6303cb73a | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Degenerative_Cortical_Intercalated_Cell_Type_A|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 6.95e-05 | 194 | 98 | 5 | b9f5f3245d0d551b6bfc76aaf0b969cdc437b3f8 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 6.95e-05 | 194 | 98 | 5 | 6165c00ec06a8393f23b0c62f679c143839b03b1 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Cortical_Collecting_Duct_Intercalated_Cell_Type_A|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 7.12e-05 | 195 | 98 | 5 | f7d9adadd37209ce1a38e5d621607b9c9270fed8 | |
| ToppCell | Control-Control-Lymphocyte-T/NK-CD4+_T_activated|Control / Disease, condition lineage and cell class | 7.65e-05 | 198 | 98 | 5 | ee71543559836fd59adc0da877b2ca538cba60cb | |
| ToppCell | mild-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 7.83e-05 | 199 | 98 | 5 | f0b0097df0026496470a80d8cc9375ffd8389b00 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_mature-Endo_capilar-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.83e-05 | 199 | 98 | 5 | 236b1417ed0875e98c6ec1ec714003bfce438d65 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-5w-Mesenchymal-Mesoderm|5w / Sample Type, Dataset, Time_group, and Cell type. | 8.02e-05 | 200 | 98 | 5 | 0927061536a664b4f7feb9e5b0a8c11ca0d5955c | |
| ToppCell | Control_saline-Endothelial-Endothelial-Activated_Alv_Cap|Control_saline / Treatment groups by lineage, cell group, cell type | 8.02e-05 | 200 | 98 | 5 | be55cef682ba87250dad97689332c8820b3a7420 | |
| ToppCell | COVID-19-COVID-19_Mild|COVID-19 / Disease, condition lineage and cell class | 8.02e-05 | 200 | 98 | 5 | 62c25042086f1afd1102e0720e933c2e476468fd | |
| Computational | Neighborhood of CDKN1C | 1.31e-05 | 27 | 59 | 4 | GNF2_CDKN1C | |
| Computational | Neighborhood of EGFR | 2.62e-05 | 32 | 59 | 4 | GNF2_EGFR | |
| Computational | Neighborhood of IGFBP1 | 3.78e-05 | 35 | 59 | 4 | GNF2_IGFBP1 | |
| Computational | Neighborhood of MMP11 | 7.84e-05 | 42 | 59 | 4 | GNF2_MMP11 | |
| Computational | Neighborhood of TIMP2 | 1.12e-04 | 46 | 59 | 4 | GNF2_TIMP2 | |
| Computational | Neighborhood of KISS1 | 1.44e-04 | 49 | 59 | 4 | GNF2_KISS1 | |
| Drug | AC1L1IPV | 1.13e-06 | 43 | 98 | 5 | CID000004683 | |
| Drug | 2,4-diamino-6-hydroxypyrimidine | 7.06e-06 | 29 | 98 | 4 | CID000002944 | |
| Drug | FAH2 | 8.31e-06 | 64 | 98 | 5 | CID000000661 | |
| Drug | tetrahydrobiopterin | 1.16e-05 | 177 | 98 | 7 | CID000001125 | |
| Drug | NSC-107146 | 1.83e-05 | 2 | 98 | 2 | CID000267616 | |
| Drug | Biopterin | 1.83e-05 | 2 | 98 | 2 | DB03886 | |
| Drug | gamma-tBAMT | 1.83e-05 | 2 | 98 | 2 | CID000125341 | |
| Drug | aditoprim | 1.83e-05 | 2 | 98 | 2 | CID000068755 | |
| Drug | 2,4-diamino-5-benzylpyrimidine | 1.83e-05 | 2 | 98 | 2 | CID000081752 | |
| Drug | methotrexate-alpha-aspartate | 1.83e-05 | 2 | 98 | 2 | CID000100376 | |
| Drug | ethyl isocyanatoacetate | 1.83e-05 | 2 | 98 | 2 | CID000076283 | |
| Drug | 3'-fluoroaminopterin | 1.83e-05 | 2 | 98 | 2 | CID000128780 | |
| Drug | DIVEMA-MTX | 1.83e-05 | 2 | 98 | 2 | CID000430857 | |
| Drug | 4-ethylacetophenone | 1.83e-05 | 2 | 98 | 2 | CID000013642 | |
| Drug | 2,4-diamino-5-phenylpyrimidine | 1.83e-05 | 2 | 98 | 2 | CID000134761 | |
| Drug | Homatropine hydrobromide (R,S) [51-56-9]; Down 200; 11.2uM; HL60; HT_HG-U133A | 2.32e-05 | 197 | 98 | 7 | 1848_DN | |
| Drug | clozapine; Up 200; 10uM; MCF7; HG-U133A | 2.48e-05 | 199 | 98 | 7 | 416_UP | |
| Drug | chloromethyl pivalate | 5.49e-05 | 3 | 98 | 2 | CID000087885 | |
| Drug | F2Glu | 5.49e-05 | 3 | 98 | 2 | CID000125424 | |
| Drug | 2,4,5,6-Tetraaminopyrimidine sulfate | 5.49e-05 | 3 | 98 | 2 | CID000070487 | |
| Drug | GNF-Pf-26 | 5.49e-05 | 3 | 98 | 2 | CID000093114 | |
| Drug | diaveridine | 5.49e-05 | 3 | 98 | 2 | CID000021453 | |
| Drug | I--254 | 5.49e-05 | 3 | 98 | 2 | CID000032285 | |
| Drug | 8-deazahomofolic acid | 5.49e-05 | 3 | 98 | 2 | CID000130665 | |
| Drug | chloroformamidine hydrochloride | 5.49e-05 | 3 | 98 | 2 | CID003084509 | |
| Drug | DMDP derivative | 5.49e-05 | 3 | 98 | 2 | CID000482165 | |
| Drug | MTX-gamma-DMPE | 5.49e-05 | 3 | 98 | 2 | CID000146936 | |
| Drug | dihydropteroylhexaglutamate | 5.49e-05 | 3 | 98 | 2 | CID000193840 | |
| Drug | L-sepiapterin | 9.98e-05 | 56 | 98 | 4 | CID000005200 | |
| Drug | pterin | 1.05e-04 | 108 | 98 | 5 | CID000073000 | |
| Drug | 5-deazaaminopterin | 1.09e-04 | 4 | 98 | 2 | CID000097272 | |
| Drug | AC1MQVYC | 1.09e-04 | 4 | 98 | 2 | CID003483303 | |
| Drug | methasquin | 1.09e-04 | 4 | 98 | 2 | CID000029335 | |
| Drug | N-benzylideneaniline | 1.09e-04 | 4 | 98 | 2 | CID000010858 | |
| Drug | ethyl 4-acetylbenzoate | 1.09e-04 | 4 | 98 | 2 | CID000600911 | |
| Drug | pY490 | 1.09e-04 | 4 | 98 | 2 | CID000283017 | |
| Drug | K 130 | 1.09e-04 | 4 | 98 | 2 | CID000467834 | |
| Drug | 2,4-diamino-6-nitroquinazoline | 1.09e-04 | 4 | 98 | 2 | CID000252163 | |
| Drug | pergularinine | 1.09e-04 | 4 | 98 | 2 | CID000264751 | |
| Drug | 5,8-dideazafolic acid | 1.09e-04 | 4 | 98 | 2 | CID003080619 | |
| Drug | AC1Q5SSM | 1.12e-04 | 22 | 98 | 3 | CID000000388 | |
| Drug | AC1L3Z4A | 1.47e-04 | 24 | 98 | 3 | CID000124807 | |
| Drug | lometrexol | 1.66e-04 | 25 | 98 | 3 | CID000001773 | |
| Drug | carbamazepine; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA | 1.74e-04 | 190 | 98 | 6 | 952_UP | |
| Drug | tylophorinidine | 1.82e-04 | 5 | 98 | 2 | CID000161749 | |
| Drug | piritrexim isethionate | 1.82e-04 | 5 | 98 | 2 | CID000054368 | |
| Drug | chlorasquin | 1.82e-04 | 5 | 98 | 2 | CID000029336 | |
| Drug | 2-desamino-2-methylaminopterin | 1.82e-04 | 5 | 98 | 2 | CID000164085 | |
| Drug | deoxytubulosine | 1.82e-04 | 5 | 98 | 2 | CID000165003 | |
| Drug | methylbenzoprim | 1.82e-04 | 5 | 98 | 2 | CID000072438 | |
| Drug | Avermectin B1 [71751-41-2]; Up 200; 4.8uM; MCF7; HT_HG-U133A | 1.84e-04 | 192 | 98 | 6 | 7218_UP | |
| Drug | Doxycycline hydrochloride [10592-13-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 1.89e-04 | 193 | 98 | 6 | 3479_DN | |
| Drug | Methionine sulfoximine (L) [15985-39-4]; Down 200; 22.2uM; MCF7; HT_HG-U133A | 1.95e-04 | 194 | 98 | 6 | 2831_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A | 1.95e-04 | 194 | 98 | 6 | 6171_DN | |
| Drug | triflate | 2.01e-04 | 67 | 98 | 4 | CID000062406 | |
| Drug | Mefenamic acid [61-68-7]; Down 200; 16.6uM; PC3; HT_HG-U133A | 2.06e-04 | 196 | 98 | 6 | 1821_DN | |
| Drug | Foliosidine [2520-38-9]; Down 200; 13uM; MCF7; HT_HG-U133A | 2.06e-04 | 196 | 98 | 6 | 6057_DN | |
| Drug | Nadolol [42200-33-9]; Down 200; 13uM; MCF7; HT_HG-U133A | 2.06e-04 | 196 | 98 | 6 | 3359_DN | |
| Drug | Mefenamic acid [61-68-7]; Up 200; 16.6uM; PC3; HT_HG-U133A | 2.06e-04 | 196 | 98 | 6 | 5109_UP | |
| Drug | Phenindione [83-12-5]; Up 200; 18uM; HL60; HG-U133A | 2.11e-04 | 197 | 98 | 6 | 1718_UP | |
| Drug | Cefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 2.11e-04 | 197 | 98 | 6 | 2235_DN | |
| Drug | Dihydroergotamine tartrate [5989-77-5]; Up 200; 3uM; MCF7; HT_HG-U133A | 2.11e-04 | 197 | 98 | 6 | 6840_UP | |
| Drug | Thiocolchicoside [602-41-5]; Up 200; 7uM; HL60; HG-U133A | 2.11e-04 | 197 | 98 | 6 | 1726_UP | |
| Drug | Ketotifen fumarate [34580-14-8]; Up 200; 9.4uM; MCF7; HT_HG-U133A | 2.11e-04 | 197 | 98 | 6 | 7199_UP | |
| Drug | Procyclidine hydrochloride [1508-76-5]; Up 200; 12.4uM; HL60; HT_HG-U133A | 2.11e-04 | 197 | 98 | 6 | 2991_UP | |
| Drug | Flunarizine dihydrochloride [30484-77-6]; Up 200; 8.4uM; MCF7; HT_HG-U133A | 2.17e-04 | 198 | 98 | 6 | 7013_UP | |
| Drug | Flunarizine dihydrochloride [30484-77-6]; Down 200; 8.4uM; PC3; HT_HG-U133A | 2.17e-04 | 198 | 98 | 6 | 7252_DN | |
| Drug | Megestrol acetate [595-33-5]; Down 200; 10.4uM; MCF7; HT_HG-U133A | 2.17e-04 | 198 | 98 | 6 | 5013_DN | |
| Drug | Etofylline [519-37-9]; Down 200; 17.8uM; MCF7; HT_HG-U133A | 2.17e-04 | 198 | 98 | 6 | 5467_DN | |
| Drug | L(-)-vesamicol hydrochloride [112709-59-8]; Down 200; 13.6uM; PC3; HT_HG-U133A | 2.17e-04 | 198 | 98 | 6 | 5056_DN | |
| Drug | ICI 182,780; Up 200; 0.01uM; MCF7; HG-U133A | 2.17e-04 | 198 | 98 | 6 | 310_UP | |
| Drug | Chlormezanone [80-77-3]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 2.17e-04 | 198 | 98 | 6 | 3235_UP | |
| Drug | Methotrexate [59-05-2]; Up 200; 8.8uM; PC3; HG-U133A | 2.23e-04 | 199 | 98 | 6 | 1957_UP | |
| Drug | Dehydroisoandosterone 3-acetate [853-23-6]; Down 200; 12.2uM; HL60; HT_HG-U133A | 2.29e-04 | 200 | 98 | 6 | 3097_DN | |
| Drug | 11-deazahomofolic acid | 2.72e-04 | 6 | 98 | 2 | CID000128960 | |
| Drug | 10-methyl-11-deazahomofolic acid | 2.72e-04 | 6 | 98 | 2 | CID000128963 | |
| Drug | 4-fluoroglutamate | 2.72e-04 | 6 | 98 | 2 | CID000102871 | |
| Drug | NBMPR-P | 2.72e-04 | 6 | 98 | 2 | CID006335125 | |
| Drug | 4-thio-5-fluoro-dUMP | 2.72e-04 | 6 | 98 | 2 | CID003035986 | |
| Disease | cD177 antigen measurement | 2.74e-07 | 18 | 93 | 4 | EFO_0021866 | |
| Disease | free cholesterol in small HDL measurement | 4.49e-06 | 35 | 93 | 4 | EFO_0022270 | |
| Disease | pregnancy-specific beta-1-glycoprotein 9 measurement | 5.87e-05 | 4 | 93 | 2 | EFO_0801909 | |
| Disease | pregnancy-specific beta-1-glycoprotein 4 measurement | 1.46e-04 | 6 | 93 | 2 | EFO_0801907 | |
| Disease | pseudohypoaldosteronism (implicated_via_orthology) | 1.46e-04 | 6 | 93 | 2 | DOID:4479 (implicated_via_orthology) | |
| Disease | lipid measurement, lipoprotein measurement | 1.92e-04 | 90 | 93 | 4 | EFO_0004529, EFO_0004732 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 1.93e-04 | 264 | 93 | 6 | EFO_0008317, EFO_0020944 | |
| Disease | sleep duration, low density lipoprotein cholesterol measurement | 2.00e-04 | 91 | 93 | 4 | EFO_0004611, EFO_0005271 | |
| Disease | cholesteryl esters to total lipids in very large HDL percentage | 2.01e-04 | 36 | 93 | 3 | EFO_0022257 | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 3.25e-04 | 291 | 93 | 6 | EFO_0008317, EFO_0020946 | |
| Disease | lipoprotein measurement | 3.47e-04 | 105 | 93 | 4 | EFO_0004732 | |
| Disease | survival time | 3.49e-04 | 9 | 93 | 2 | EFO_0000714 | |
| Disease | cholesteryl ester measurement, high density lipoprotein cholesterol measurement | 4.70e-04 | 312 | 93 | 6 | EFO_0004612, EFO_0010351 | |
| Disease | total lipids in lipoprotein particles measurement | 4.73e-04 | 48 | 93 | 3 | EFO_0022309 | |
| Disease | cholesteryl esters to total lipids in small VLDL percentage | 5.03e-04 | 49 | 93 | 3 | EFO_0022256 | |
| Disease | omega-3 polyunsaturated fatty acid measurement | 5.39e-04 | 118 | 93 | 4 | EFO_0010119 | |
| Disease | cholesterol to total lipids in small VLDL percentage | 5.66e-04 | 51 | 93 | 3 | EFO_0022242 | |
| Disease | alcohol consumption measurement, alcohol drinking | 6.35e-04 | 12 | 93 | 2 | EFO_0004329, EFO_0007878 | |
| Disease | Antithrombotic agent use measurement | 7.06e-04 | 55 | 93 | 3 | EFO_0009925 | |
| Disease | docosahexaenoic acid measurement | 7.11e-04 | 127 | 93 | 4 | EFO_0007761 | |
| Disease | level of Phosphatidylinositol (18:1_18:1) in blood serum | 7.49e-04 | 13 | 93 | 2 | OBA_2045159 | |
| Disease | phospholipids:total lipids ratio | 7.73e-04 | 227 | 93 | 5 | EFO_0020946 | |
| Disease | platelet storage pool deficiency (implicated_via_orthology) | 1.00e-03 | 15 | 93 | 2 | DOID:2223 (implicated_via_orthology) | |
| Disease | cholesterol:total lipids ratio, low density lipoprotein cholesterol measurement | 1.13e-03 | 144 | 93 | 4 | EFO_0004611, EFO_0020943 | |
| Disease | cholesteryl ester measurement | 1.34e-03 | 257 | 93 | 5 | EFO_0010351 | |
| Disease | low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 1.42e-03 | 153 | 93 | 4 | EFO_0004611, EFO_0020946 | |
| Disease | level of Phosphatidylinositol (18:0_18:1) in blood serum | 1.45e-03 | 18 | 93 | 2 | OBA_2045155 | |
| Disease | cancer (implicated_via_orthology) | 1.61e-03 | 268 | 93 | 5 | DOID:162 (implicated_via_orthology) | |
| Disease | level of Phosphatidylinositol (18:0_18:2) in blood serum | 1.98e-03 | 21 | 93 | 2 | OBA_2045156 | |
| Disease | Malignant neoplasm of breast | 2.06e-03 | 1074 | 93 | 10 | C0006142 | |
| Disease | proprotein convertase subtilisin/kexin type 9 measurement | 2.18e-03 | 22 | 93 | 2 | EFO_0009312 | |
| Disease | level of Phosphatidylinositol (18:0_20:4) in blood serum | 2.38e-03 | 23 | 93 | 2 | OBA_2045158 | |
| Disease | lipoprotein measurement, phospholipid measurement | 2.48e-03 | 85 | 93 | 3 | EFO_0004639, EFO_0004732 | |
| Disease | free cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement | 2.75e-03 | 303 | 93 | 5 | EFO_0004612, EFO_0020945 | |
| Disease | phospholipids:total lipids ratio, high density lipoprotein cholesterol measurement | 2.91e-03 | 307 | 93 | 5 | EFO_0004612, EFO_0020946 | |
| Disease | Pancytopenia | 3.04e-03 | 26 | 93 | 2 | C0030312 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TQLKLPIVPSLQRLL | 1276 | Q9HCE0 | |
| RKRLAIALELVNNPP | 206 | Q9H172 | |
| EVLPRLETLLQPRKR | 786 | O95696 | |
| KPLLLIVPLRLGINQ | 221 | Q8WYN0 | |
| PREPKRNRIILNLKV | 166 | O95503 | |
| LPNFLVQRKVLRPLR | 101 | Q96DB2 | |
| PERVEKIRKLPNTLL | 51 | Q53H64 | |
| RILNPNKAPLRLKLR | 746 | O75843 | |
| ILKKERPNRLPLLEF | 1711 | Q8IYW2 | |
| LQKTRPPRKLELRQL | 271 | P32238 | |
| LQRPPQNLLRLLRKA | 251 | Q9UMQ6 | |
| PRLRPRLNAILFKLQ | 931 | O60610 | |
| ILKNPQLQAAIRVLP | 41 | Q9BZG8 | |
| LPQLIIPIKNALNLR | 146 | Q96M98 | |
| LARKRIPPDVPILLN | 266 | Q8NGH8 | |
| VPNVLLAKREELIPL | 531 | Q9P260 | |
| LLEQVLLVLEPPRLQ | 331 | Q86U38 | |
| NRERPLLLEEQPLLL | 3041 | Q8NEZ4 | |
| LKRLRDPLQVHLPLR | 331 | Q8NE86 | |
| ILRFLERKEQIPLKP | 491 | P46199 | |
| PRQVRLLQRLKTKPL | 36 | Q86UX2 | |
| LPHLRCPLQRLVLRK | 891 | Q86W28 | |
| LERLFKQLHPQLLLP | 171 | P35052 | |
| LEPVLLLLLQPKTQR | 996 | Q9Y3R5 | |
| KDQPRVLLPLANVAL | 61 | Q13144 | |
| LRKVPNIIDLLAILP | 271 | Q6PIU1 | |
| LVLRDNKIRQLPELP | 196 | Q99645 | |
| PLQLNLLQLEELPRA | 981 | O15534 | |
| VNQLLLLDPPRKRLV | 96 | O15031 | |
| IVQIAPQSLILKLRP | 101 | P18564 | |
| RKPELERPIKVNLAL | 421 | Q01650 | |
| LPILRVLNLLENPIQ | 326 | Q96M69 | |
| RGPLRKLVLQSLVPL | 521 | A6NGR9 | |
| DQRPSPKLVLIILQL | 1416 | Q9Y4D8 | |
| IIAKRLPPDQLISLL | 1041 | Q8NDA8 | |
| LPPLLLKLNERPAER | 691 | Q9H0A0 | |
| NIVEVLPHLPRLRKL | 761 | Q86WI3 | |
| LARKRIPPDVPILLN | 266 | P0C7T3 | |
| QRRKKGLLLRPVAPL | 111 | Q9NPB6 | |
| VLRRQILLPFRKPLI | 841 | Q02218 | |
| LLRPAAQIRTKQLQP | 341 | Q96A11 | |
| REALQPLLTQRLPQL | 2011 | Q96HP0 | |
| LKEALQPLINRKIPQ | 2101 | Q96N67 | |
| SLPLPNQLEIALRKI | 1446 | O15078 | |
| RQLRNEKDKPLPPLL | 1386 | Q12873 | |
| LLKQQLPEIQRVPLE | 986 | Q6P158 | |
| RINLVLSRELKEPPQ | 71 | P00374 | |
| KRELRNLVPLLLAPE | 321 | Q8NHH9 | |
| PATRIVLILPLDKRQ | 41 | Q9BQM9 | |
| VLILPLDKRQPLANA | 46 | Q9BQM9 | |
| RINLVLSRELKEPPQ | 71 | Q86XF0 | |
| HLLPLDQRLLIKNPR | 276 | Q9UH77 | |
| ALFLLLQRKNLRRPP | 16 | Q9NYL5 | |
| PKAIQDQLPRLQQLL | 281 | Q9HB96 | |
| KLRQRLGLQLLELPP | 51 | O95865 | |
| LELAQVLAQERPKLP | 1196 | P49327 | |
| RKELRPPDLAQRVQL | 131 | Q92902 | |
| VKRPIENRILILPNV | 286 | Q00888 | |
| QLQRLRELLLQPPTE | 866 | Q13474 | |
| VKRPIENRILILPSV | 286 | P11464 | |
| LLRLALEQLLEQLPP | 231 | Q6P5Z2 | |
| VKRPIENRILILPSV | 286 | Q16557 | |
| HLLGQLRKPRPLVLD | 686 | Q9Y6K5 | |
| DLPAPQKLLARLLVL | 571 | A6NES4 | |
| LIRKLLVLDPQQRLA | 306 | Q8N2I9 | |
| QILKIRLLPGHPRRL | 916 | A6NHR9 | |
| QVADKLPRPNLLLLK | 196 | Q8N103 | |
| LKVVPEELLNLPRLS | 1831 | B5MCY1 | |
| QPDRKQLPLVLLRLL | 6 | Q13449 | |
| PVVLFPIRRALQQLL | 351 | Q8WUX1 | |
| RLLLKLQRLPQAEPV | 16 | Q71RC9 | |
| IPNPVDLRLNIIKSL | 1166 | Q9NTG1 | |
| VKRPIENRILILPSV | 286 | Q9UQ74 | |
| VKRPIENRILILPSV | 286 | Q00887 | |
| VIRQLLPKAPPLREL | 76 | O14793 | |
| LRPQSRPQIIKEVLA | 556 | Q9H3S1 | |
| ELPLVPVKRQRHELL | 11 | Q96DI7 | |
| SQRRPLLLQVLKELL | 326 | Q9Y4R8 | |
| LLLLQRLKNRLLPPA | 821 | Q9Y4R8 | |
| VKTPIPLLLRGQLRE | 606 | Q6ZRS2 | |
| VKLPSPQQLLARLLV | 501 | Q7Z745 | |
| LNILEENIRRLLPLP | 826 | Q7Z745 | |
| IKRQPKVVERLLSLP | 521 | Q9H0H5 | |
| QPLDLLKTRLQTLQP | 46 | Q96DW6 | |
| NILLVRLLDGIKQRP | 66 | Q7Z6J0 | |
| IRILLQKLRPPDIRK | 316 | P32241 | |
| LLKPVLGVLRVRPQN | 651 | P41226 | |
| RNRLLKFPEIVAPLL | 251 | Q03426 | |
| LLPEPRILQKLAVPI | 171 | Q9BQR3 | |
| LQQLLGALRELPRPK | 76 | P35270 | |
| LPRPKGLQRLLLINN | 86 | P35270 | |
| LKRLIAKRPPLQSLQ | 516 | Q9BRR9 | |
| SLLKLFIRELPQPLL | 401 | Q8N392 | |
| TPKQLRLINQPLPDL | 1656 | P11137 | |
| ILNNEKLVLPPRISR | 16 | Q9H8X9 | |
| VRKLLLLIPTDPAIQ | 1101 | Q9UPU5 | |
| RPLPSIRILVDKINL | 686 | Q7Z7G8 | |
| QPPQPLQRRVLLLCK | 66 | Q9Y3S1 | |
| PDAKVRIIPLQLQRL | 86 | Q9NVE5 | |
| QKPRLLEENALPVLQ | 176 | Q9Y2L8 | |
| LKRNISPKIPRLLLA | 121 | Q9NYW5 | |
| IPKLLRELVPQDLIR | 2056 | Q13402 |